查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1848813

葛瑞夫茲氏病市場按診斷、治療類型、年齡層、給藥途徑和分銷管道分類－2025-2032 年全球預測

Graves Disease Market by Diagnosis, Treatment Type, Age Group, Route Of Administration, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，葛瑞夫茲氏病市場規模將成長至 10.1986 億美元，複合年成長率為 5.97%。

主要市場統計數據
基準年2024年 6.4122億美元
預計2025年 6.772億美元
預測年份：2032年 10.1986億美元
複合年成長率（%） 5.97%

簡潔的臨床和策略概述表葛瑞夫茲氏病是一種多學科的醫療保健挑戰，需要綜合診斷和量身定做的治療途徑

葛瑞夫茲氏病是一種複雜的自體免疫甲狀腺疾病，其全身性影響遠遠超出了內分泌臨床的範圍。臨床上，此病的特徵是由針對甲狀腺刺激素受體的刺激性抗體引起的甲狀腺功能亢進，但其影響是多方面的，會影響心血管健康、眼科功能、代謝狀態和患者生活品質。準確的診斷和及時的治療性介入對於降低發病率、預防長期併發症以及最佳化不同患者群體的功能結果至關重要。因此，包括診斷實驗室、製藥商、醫療保健提供者、付款人和患者權益團體在內的相關人員越來越認知到需要整合的護理途徑，強調精準診斷、個人化治療選擇和持續的後續護理。

在這種臨床環境下，醫療格局正在迅速演變。改進的免疫檢測、影像技術和數位健康平台正在重塑診斷工作流程，包括生物目標和複雜的放射性碘通訊協定在內的治療創新正在改變治療流程，支付方也在重新調整覆蓋框架，以反映基於結果的優先事項。鑑於這些多方面的變化，領導者必須綜合臨床證據、監管趨勢和營運現實，以調整優先考慮以患者為中心的治療策略，同時保持財務責任。本引言將重點放在持續存在的臨床挑戰以及醫療服務、診斷和治療創新領域轉型改善的機遇，為後續分析組裝。

診斷進展、治療方法創新和醫療服務轉型將重塑護理途徑和相關人員合作

在過去的幾年中，由於診斷、治療方案和醫療保健提供模式的進步，葛瑞夫茲氏病的檢測、監測和治療方法發生了變革性的變化。隨著 TSH 受體抗體血清學檢測更加靈敏和特異性，以及成像方式更加複雜，診斷準確性得到了提高，使臨床醫生能夠更有效地對患者進行分層並減少診斷的不確定性。同時，治療模式也在不斷發展。雖然抗甲狀腺藥物和放射性碘治療仍然是主要治療方法，但人們對有針對性的免疫調節方法和個人化給藥策略的興趣日益濃厚，以減少過度治療和不利事件。這些臨床變化伴隨著更廣泛的系統級轉變，包括將遠端醫療整合到內分泌追蹤中、遠端監測甲狀腺功能測試以及支持藥物依從性和症狀追蹤的數位工具。

同時，監管和報銷環境正在根據證明標靶診斷和治療價值的證據進行調整，鼓勵專科中心和一些醫療系統儘早採用精準醫療工具。由於相關人員力求確保放射性藥物和檢測試劑等關鍵投入，供應鏈的韌性和本地製造能力也變得越來越重要。總而言之，這些轉變將推動一個更精細的生態系統，在這個生態系統中，臨床醫生、診斷開發人員和治療方法創新者將攜手合作，提供循證、可擴展且永續的以患者為中心的醫療服務。

對 2025 年關稅對醫用同位素、診斷試劑和醫療設備採購的影響進行策略性評估，並進行必要的調整以確保臨床連續性。

2025年《政策與貿易發展報告》引入了新的關稅措施，這些措施對與葛瑞夫茲氏病治療相關的醫療投入產生了微妙的影響。影響醫用同位素、專用診斷劑和某些醫療設備進口的關稅調整，增加了醫院和實驗室採購的複雜性。因此，採購團隊在採購促甲狀腺激素受體檢測試劑、用於治療和攝取研究的放射性碘以及超音波和核醫學設備時，必須應對成本結構的變化、供應商合約的更新以及潛在的前置作業時間波動。這些營運影響促使服務供應商重新評估供應商多元化，增加關鍵項目的庫存緩衝，並尋求長期採購協議，以保護臨床服務免受短期貿易波動的影響。

此外，關稅主導的採購轉變正在加速考慮國內生產方案和區域供應商網路，以降低跨境不確定性帶來的風險。衛生系統和診斷實驗室正在評估本地製造外包和集中供應安排，以保持醫療服務的連續性。重要的是，監管機構和相關人員正密切關注其對醫療可近性的影響。如果關稅增加了提供某些診斷測試或治療的成本，相關人員可能需要與付款人合作，調整報銷政策，或探索在保持臨床療效的同時控制成本的替代醫療模式。應對這些挑戰需要跨職能規劃、積極的相關人員參與以及基於場景的營運方案。

綜合細分分析將診斷方式、治療方法、患者群體、配送路線和分銷管道與可操作的臨床和商業性優先事項聯繫起來

此細分為理解葛瑞夫茲氏病的異質性臨床路徑和商業性動態提供了分析立足點。根據診斷，市場研究涵蓋血液檢測、影像檢查和身體檢查。血液檢測進一步細分為游離4碘甲狀腺素和T3水平、甲狀腺刺激素(TSH) 水平和TSH受體抗體，而影像檢查包括放射性碘攝取試驗和甲狀腺超音波。這些診斷區別非常重要，因為它們可以作為臨床決策點，區分抗體介導的甲狀腺功能亢進與其他病因，確定基於影像學定位的必要性，並指導監測強度。

從治療角度來看，按治療類型細分可區分抗甲狀腺藥物、 BETA阻斷劑和放射性碘治療，反映出不同的療效、安全性和監測要求，這些要求會影響採購、報銷和患者教育計畫。按成人、老年人和兒童年齡層細分可突顯臨床表現、併發症負擔和治療耐受性的差異，進而影響臨床指引和治療優先順序。依給藥途徑（靜脈注射與口服）細分可捕捉醫療環境、給藥基礎設施和依從性考量的差異。最後，按分銷管道（醫院藥房、線上藥房和零售藥房）細分會影響取得、配藥工作流程和病患支援服務。結合這些細分視角，可以明確臨床需求、交付機制和機會的交集，為診斷開發商、治療藥物製造商和醫療保健提供者提供量身定做的策略。

從區域角度檢驗醫療保健基礎設施、法規環境和獲取動態如何影響全球市場的診斷採用和治療交付

區域動態顯著影響著葛瑞夫茲氏病的治療傳遞和技術創新的採用，美洲、歐洲、中東和非洲以及亞太地區呈現出明顯的區域動態變化模式。在美洲，強大的診斷基礎設施和一體化的專家網路促進了先進檢測方法和多學科診所的早期應用。然而，都市區/服務欠缺地區之間存在差異，因此需要系統層面的努力來擴大可近性和基於遠端醫療的監測。在歐洲、中東和非洲，多樣化的法律規範和異質的報銷環境決定了新診斷和新治療方法惠及患者的速度，而成熟的專業中心通常充當最佳實踐方案和臨床研究合作的中心。重要的是，許多國家醫療保健系統強調以指南主導的護理和基於價值的報銷，從而影響了高成本創新的採用曲線。

醫療保健基礎設施的快速投資、診斷能力的提升以及臨床研究活動的擴展，正在加速亞太地區新型診斷和治療方法的引入，但供應鏈集中度和區域製造限制可能會影響放射性藥物和專用試劑的可得性。由於該地區內分泌疾病的盛行率、人口年齡結構和內分泌科醫生的可及性存在差異，因此需要採取針對具體情況的策略，例如在某些市場開展公共衛生計畫和醫療服務提供者教育宣傳活動，在其他市場開展有針對性的報銷合作，以及在跨境依賴程度較高的地區開展旨在增強供應鏈韌性的商業投資。這些區域洞察凸顯了需要採取因地制宜的策略，以平衡臨床優先事項與系統能力和政策現實。

企業優先事項的影響分析，強調診斷創新、治療差異化、供應鏈穩健性以及持續影響的綜合商業化策略

葛瑞夫茲氏病生態系中的企業策略正圍繞著幾個一致的優先事項：提高診斷準確性、最佳化治療安全性和有效性，以及加強供應鏈和商業化能力。診斷公司正在投資高靈敏度的促甲狀腺激素受體免疫測量，以及將血清學結果與影像數據關聯起來以支持臨床醫生決策的整合平台。製藥和生物技術開發公司正在尋求差異化的抗甲狀腺藥物、更安全的放射性碘治療給藥方案以及針對潛在自體免疫機制的生物製藥，這促使臨床研究中心和研發公司之間建立了許多合作夥伴關係，以加速轉化途徑。

在商業性，各公司專注於透過多種分銷策略擴大藥品供應，包括與醫院藥房合作、專業分銷協議和數位配藥管道。他們還在實施生產規模擴大和供應品質提升計劃，以滿足放射性藥物和試劑製造的獨特需求。此外，與診斷實驗室和醫療系統的策略合作夥伴關係能夠收集真實世界證據，以支持報銷申請。此外，各公司正在投資患者支持和依從性項目，以減少治療中斷並改善臨床療效。總而言之，這些公司的優先事項凸顯了向整合解決方案的轉變，這些解決方案將診斷、治療和服務整合在一起，從而為患者照護帶來可衡量的改善。

為領導者提供實用的策略舉措，整合診斷準確性、供應鏈彈性、付款人參與度和患者訪問模式，以推動臨床和商業性成功

行業領導者必須採取積極主動、以患者為中心的方法，在利用臨床進展的同時降低營運風險。首先，他們將投資於整合診斷生態系統，支援採用高度特異性的檢測和影像工作流程，以實現準確的患者分層並減少診斷延遲。此外，他們將優先制定強調不同年齡層安全性和耐受性的治療策略，同時將資源分配給能夠產生比較有效性和真實世界證據以支持付款方論點的臨床項目。其次，他們將透過供應商多元化、區域製造夥伴關係以及放射性藥物和檢測試劑等關鍵投入的庫存管理實踐來增強供應鏈的韌性，從而降低貿易中斷和關稅波動帶來的脆弱性。

第三，透過混合配送和照護模式擴大患者可近性，將醫院服務與遠端醫療支援的追蹤和藥房藥物配送結合。這包括與藥房和數位健康平台合作，以提高依從性和監測能力。第四，儘早與監管機構和付款方進行透明的溝通，使臨床開發與循證要求保持一致，並在適當情況下考慮基於價值的合約。最後，投資於內分泌科、核醫和初級保健領域的勞動力發展，以確保符合指南的管理，並促進新診斷和治療方法的採用。實施這些建議將有助於組織在技術創新的採用與營運永續性和改善患者預後之間取得平衡。

透明且可複製的混合方法研究框架，結合系統文獻綜述、專家訪談和數據三角測量，以確保臨床和操作有效性

該研究方法將嚴格的二次證據審查與有針對性的原始資料收集相結合，以確保分析的穩健性和臨床相關性。二次研究系統地回顧了同行評審文獻、臨床指南、監管文件和供應商技術規範，以建立關於病理學、診斷技術和治療方法，以了解第一線實踐、未滿足的需求和實施障礙。數據三角檢驗對資訊來源的研究結果進行了交叉檢驗，並透過後續專家諮詢和敏感性檢查解決了差異。

調查方法保障措施包括：明確的臨床試驗和產品評估納入和排除標準、透明的訪談通訊協定和受訪者角色記錄，以及對專家見解進行定性編碼以識別重複出現的主題。地域覆蓋範圍確保了均衡的市場代表性，以反映醫療保健服務和監管格局。該研究也承認其局限性，包括不斷變化的臨床證據和不同地區數據可用性的潛在差異，並建議定期更新並針對優先子主題進行有針對性的初步研究。總體而言，該調查方法強調可重複性、同儕檢驗以及對參與葛瑞夫茲氏病治療和商業策略的相關人員的實際意義。

簡潔、全面的分析，重點在於診斷和治療方面的進展，以及需要採取協調策略行動的供應鏈和政策挑戰

這項分析強調，葛瑞夫茲氏病的管理正處於曲折點，改進的診斷方法、創新的治療方法方案和切實可行的營運規劃將塑造未來的治療標準。血清學檢測和影像技術的進步使得診斷更早、更準確成為可能，不斷發展的治療方法方案和護理模式有望提高安全性並帶來以患者為中心的治療效果。然而，這些機會也與系統性挑戰並存，包括供應鏈脆弱性、與關稅相關的採購複雜性以及區域差異化的採用模式，需要我們採取有針對性的策略性應對措施。

摘要，那些能夠將臨床開發與營運約束相結合、投資於彈性供應和分銷網路、並積極與相關人員和監管機構合作的相關人員，將最有能力將科學進步轉化為切實的患者利益。重視整合護理路徑、證據生成和可擴展的交付模式，將加速創新技術的採用，從而改善葛瑞夫茲氏病病患者的生活品質，同時維持永續的組織績效。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 採用針對 B 細胞調節的生物目標療法治療難治性疾病
  • 穿戴式甲狀腺功能監測設備的整合可實現即時 TSH 追蹤和病人參與
  • 擴展的遠距內分泌平台促進葛瑞夫茲氏病病患者的遠距離診斷和治療協調
  • 新型小分子促甲狀腺激素受體拮抗劑獲監理機關核准，擴大非侵入性治療選擇
  • 增加抗甲狀腺藥物與免疫調節劑的聯合治療通訊協定，以降低復發率
  • 以患者為中心的數位健康應用程式的出現，支持葛瑞夫茲氏病的症狀追蹤和藥物依從性
  • 高強度聚焦超音波作為葛瑞夫茲氏病眼疾治療非手術替代方法的臨床應用

第6章：2025年美國關稅的累積影響

第7章：人工智慧的累積影響，2025年

第 8 章葛瑞夫茲氏病市場（按診斷）

  • 血液檢查
    • 游離4碘甲狀腺素和 T3 水平
    • 甲狀腺刺激素（TSH）水平
    • TSH受體抗體（TSH-RAb）
  • 影像檢查
    • 放射性碘的吸收
    • 甲狀腺超音波
  • 身體檢查

第9章葛瑞夫茲氏病市場（依治療類型）

  • 抗甲狀腺藥物
  • BETA受體阻斷劑
  • 放射性碘治療

第 10 章葛瑞夫茲氏病市場（按年齡層）

  • 成人
  • 老年人
  • 孩子們

第11章葛瑞夫茲氏病市場按管理途徑

  • 靜脈
  • 口服

第 12 章葛瑞夫茲氏病市場按分銷管道分類

  • 醫院藥房
  • 網路藥局
  • 零售藥局

第13章葛瑞夫茲氏病市場：按地區

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第 14 章葛瑞夫茲氏病市場：按組

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章葛瑞夫茲氏病市場（按國家）

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Abbott Laboratories
    • AdvanceCor GmbH
    • Cadila Pharmaceuticals Limited
    • CORONA Remedies Limited
    • Daxia Healthcare Pvt Ltd.
    • Eris Lifesciences Ltd
    • F. Hoffmann-La Roche Ltd.
    • Immunovant, Inc. by Roivant Sciences Ltd.
    • LGM Pharma
    • Macleods Pharmaceuticals Ltd.
    • Merck KGaA
    • Novartis AG
    • Pfizer Inc.
    • Salvavidas Pharmaceutical Pvt. Ltd.
    • Siemens Healthineers AG
    • Steris Healthcare Pvt Ltd
    • Sun Pharmaceutical Industries Ltd
    • Synmedic Laboratories by Dhanuka Laboratories Limited
    • Teva Pharmaceutical Industries Ltd.
    • Thermo Fisher Scientific Inc.
    • Wellona Pharma
Product Code: MRR-42653751EADD

The Graves Disease Market is projected to grow by USD 1,019.86 million at a CAGR of 5.97% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 641.22 million
Estimated Year [2025] USD 677.20 million
Forecast Year [2032] USD 1,019.86 million
CAGR (%) 5.97%

A concise clinical and strategic overview that frames Graves disease as a multidisciplinary healthcare challenge demanding integrated diagnostics and tailored therapeutic pathways

Graves disease represents a complex autoimmune thyroid disorder with systemic implications that extend far beyond endocrinology clinics. Clinically, it is characterized by hyperthyroidism driven by stimulating antibodies against the thyroid-stimulating hormone receptor, but its impact is multidisciplinary-affecting cardiovascular health, ophthalmic function, metabolic status, and patient quality of life. Accurate diagnosis and timely therapeutic intervention are essential to reduce morbidity, prevent long-term complications, and optimize functional outcomes for diverse patient populations. Consequently, stakeholders across diagnostic labs, pharmaceutical manufacturers, providers, payers, and patient advocacy groups increasingly recognize the need for integrated care pathways that emphasize precision diagnostics, individualized treatment selection, and continuity of follow-up care.

Against this clinical backdrop, the landscape is evolving rapidly: improvements in immunoassays, imaging techniques, and digital health platforms are reshaping diagnostic workflows; therapeutic innovation including targeted biologics and refined radioiodine protocols is altering treatment algorithms; and payers are recalibrating coverage frameworks to reflect outcomes-based priorities. Given this multifaceted shift, leaders must synthesize clinical evidence, regulatory developments, and operational realities to adapt strategies that prioritize patient-centric outcomes while maintaining fiscal responsibility. This introduction frames the subsequent analysis by highlighting both the persistent clinical challenges and the opportunities for transformative improvement across care delivery, diagnostics, and therapeutic innovation.

An exploration of diagnostic advances, therapeutic innovation, and healthcare delivery transformation reshaping care pathways and stakeholder collaborations

The last several years have seen transformative shifts in how Graves disease is detected, monitored, and treated, driven by advances in diagnostics, therapeutic options, and healthcare delivery models. Diagnostic precision has improved through more sensitive and specific serological assays for TSH receptor antibodies and refined imaging modalities, enabling clinicians to stratify patients more effectively and reduce diagnostic uncertainty. Simultaneously, therapeutic paradigms are evolving: while antithyroid medications and radioiodine therapy remain mainstays, there is accelerating interest in targeted immunomodulatory approaches and personalized dosing strategies that reduce overtreatment and adverse events. These clinical changes are accompanied by broader system-level shifts, including the integration of telemedicine into endocrine follow-up, remote monitoring of thyroid function tests, and digital tools that support medication adherence and symptom tracking.

In parallel, regulatory and reimbursement environments are adapting to evidence demonstrating value in targeted diagnostics and therapies, prompting earlier adoption of precision tools in specialist centers and select health systems. Supply chain resilience and localized manufacturing capacity have also risen in importance, as stakeholders aim to secure critical inputs such as radiopharmaceuticals and assay reagents. Collectively, these shifts are driving a more nuanced ecosystem in which clinicians, diagnostics developers, and therapeutic innovators collaborate to deliver patient-centered care pathways that are evidence-informed, scalable, and sustainable.

A strategic assessment of 2025 tariff effects on medical isotope, diagnostic reagent, and device procurement and the operational adjustments required to protect clinical continuity

Policy and trade developments in 2025 introduced new tariff measures that have nuanced implications for medical inputs relevant to Graves disease care. Tariff adjustments affecting imports of medical isotopes, specialized diagnostic reagents, and certain medical devices have raised procurement complexity for hospitals and laboratories. As a result, purchasing teams must navigate altered cost structures, updated supplier contracts, and potential lead-time variability when acquiring reagents for TSH receptor assays, radioactive iodine supplies for therapy and uptake studies, and ultrasound and nuclear medicine equipment. These operational impacts have prompted service providers to reassess vendor diversification, increase inventory buffers for critical items, and pursue longer-term purchasing agreements to insulate clinical services from short-term trade fluctuations.

Moreover, tariff-driven procurement shifts are accelerating consideration of domestic production options and regional supplier networks to reduce exposure to cross-border uncertainties. Health systems and diagnostic labs are increasingly evaluating local contract manufacturing and collaborative supply arrangements to maintain continuity of care. Importantly, regulators and payers are mindful of access implications; where tariffs raise the cost of delivering specific diagnostic tests or therapies, stakeholders may need to work with payers to adjust reimbursement policies or explore alternative care models that preserve clinical outcomes while containing costs. Transitioning through these challenges requires cross-functional planning, proactive stakeholder engagement, and scenario-based operational playbooks to ensure patient access is maintained while organizations adapt to evolving trade realities.

An integrative segmentation analysis linking diagnostic modalities, therapeutic approaches, patient cohorts, delivery routes, and distribution channels to actionable clinical and commercial priorities

Segmentation provides the analytical scaffolding to understand heterogeneous clinical pathways and commercial dynamics in Graves disease, beginning with diagnostic modalities. Based on diagnosis, the market is examined across blood tests, imaging tests, and physical examination; blood tests are further delineated into Free T4 and T3 levels, thyroid-stimulating hormone (TSH) levels, and TSH receptor antibodies, while imaging tests include radioactive iodine uptake studies and thyroid ultrasound. These diagnostic distinctions matter because they drive clinical decision points-differentiating antibody-mediated hyperthyroidism from other etiologies, defining the need for imaging-based localization, and informing the intensity of monitoring.

From a treatment perspective, segmentation by treatment type distinguishes antithyroid medications, beta-blockers, and radioactive iodine therapy, reflecting different efficacy, safety, and monitoring requirements that influence procurement, reimbursement, and patient education programs. Age group segmentation across adult, elderly, and pediatric cohorts highlights variability in presentation, comorbidity burden, and treatment tolerability, which in turn affects clinical guidelines and therapeutic prioritization. Segmentation by route of administration-intravenous versus oral-captures differences in care setting, administration infrastructure, and adherence considerations. Finally, distribution channel segmentation across hospital pharmacies, online pharmacies, and retail pharmacies influences access, dispensing workflows, and patient support services. Taken together, these segmentation lenses enable tailored strategies for diagnostics developers, therapeutics manufacturers, and healthcare providers by clarifying where clinical needs, delivery mechanisms, and commercial opportunities intersect.

A region-by-region examination of healthcare infrastructure, regulatory environments, and access dynamics shaping diagnostic adoption and therapeutic delivery across global markets

Regional dynamics exert profound influence on care delivery and innovation adoption for Graves disease, with distinct patterns emerging across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, robust diagnostic infrastructure and integrated specialist networks facilitate early adoption of advanced assays and multidisciplinary clinics; yet disparities persist between urban centers and rural or underserved communities, prompting system-level initiatives to expand access and telehealth-enabled monitoring. In Europe, Middle East & Africa, varied regulatory frameworks and heterogeneous reimbursement environments shape the pace at which new diagnostics and therapies reach patients, while established specialty centers often serve as hubs for best-practice protocols and clinical research collaborations. Importantly, national health systems in many countries emphasize guideline-driven care and value-based reimbursement, affecting adoption curves for higher-cost innovations.

Across Asia-Pacific, rapid investment in healthcare infrastructure, increasing diagnostic capacity, and expanding clinical research activity are accelerating uptake of novel diagnostics and therapeutic options, although supply chain concentration and regional manufacturing constraints can affect availability of radiopharmaceuticals and specialized reagents. Throughout all regions, differences in prevalence, population age structures, and access to endocrinology specialists demand context-specific strategies: public health programs and provider education campaigns in some markets, targeted reimbursement engagement in others, and operational investments in supply chain resilience where cross-border dependencies are pronounced. These regional insights highlight the need for geographically attuned approaches that balance clinical priorities with system capabilities and policy realities.

An analysis of corporate priorities emphasizing diagnostic innovation, therapeutic differentiation, supply chain robustness, and integrated commercialization strategies for sustained impact

Company strategies in the Graves disease ecosystem are converging on several consistent priorities: advancing diagnostic precision, optimizing therapeutic safety and efficacy, and strengthening supply chain and commercialization capabilities. Diagnostic firms are investing in higher-sensitivity immunoassays for TSH receptor antibodies and in integrated platforms that link serology results with imaging data to support clinician decision-making. Pharmaceutical and biotech developers are pursuing differentiated antithyroid agents, safer dosing regimens for radioiodine therapy, and biologic candidates that target underlying autoimmune mechanisms, with many partnerships forming between clinical research centers and developers to accelerate translational pathways.

Commercially, companies focus on expanding access through diversified distribution strategies that include hospital pharmacy partnerships, specialty distribution contracts, and digital dispensing channels. Manufacturing scale-up and quality-of-supply initiatives address the unique demands of radiopharmaceuticals and reagent production, while strategic collaborations with diagnostic labs and health systems enable real-world evidence collection to support reimbursement dossiers. Additionally, companies are investing in patient support and adherence programs that reduce treatment discontinuation and improve clinical outcomes. Taken together, these corporate priorities underscore a shift toward integrated solutions that combine diagnostics, therapeutics, and services to deliver measurable improvements in patient care.

Practical strategic initiatives for leaders to integrate diagnostic precision, supply chain resilience, payer engagement, and patient access models to drive clinical and commercial success

Industry leaders must adopt a proactive, patient-centered approach to capitalize on clinical advances while mitigating operational risks. First, invest in diagnostic ecosystem integration by supporting the adoption of high-specificity assays and imaging workflows that enable precise patient stratification and reduce diagnostic delay. Coupled with that, prioritize development of therapeutic strategies that emphasize safety and tolerability for diverse age cohorts, while allocating resources toward clinical programs that generate comparative effectiveness and real-world evidence to support payer discussions. Second, fortify supply chain resilience through supplier diversification, regional manufacturing partnerships, and inventory management practices for critical inputs such as radiopharmaceuticals and assay reagents, thereby reducing vulnerability to trade disruptions and tariff volatility.

Third, expand patient access via hybrid distribution and care models that blend hospital-based services with telehealth-enabled follow-up and pharmacy-based medication delivery. This includes partnering with pharmacies and digital health platforms to improve adherence and monitoring. Fourth, engage early and transparently with regulators and payers to align clinical development with evidentiary requirements and to explore value-based contracting where appropriate. Finally, invest in workforce training across endocrinology, nuclear medicine, and primary care to ensure guideline-concordant management and to accelerate uptake of emerging diagnostics and therapies. Implementing these recommendations will help organizations balance innovation adoption with operational sustainability and improved patient outcomes.

A transparent and reproducible mixed-methods research framework combining systematic literature review, expert interviews, and data triangulation to ensure clinical and operational validity

The research approach combines rigorous secondary evidence review with targeted primary data collection to ensure analytical robustness and clinical relevance. Secondary research entailed systematic review of peer-reviewed literature, clinical guidelines, regulatory documents, and vendor technical specifications to establish a comprehensive knowledge base on pathophysiology, diagnostic technologies, and therapeutic modalities. Primary research complemented this foundation through structured interviews with endocrinologists, nuclear medicine specialists, laboratory directors, pharmacists, and health system procurement leaders to capture frontline operational realities, unmet needs, and adoption barriers. Data triangulation ensured findings were cross-validated across sources, with discrepancies resolved through follow-up expert consultations and sensitivity checks.

Methodological safeguards included explicit inclusion and exclusion criteria for clinical studies and product assessments, transparent documentation of interview protocols and respondent roles, and qualitative coding of expert insights to identify recurrent themes. Geographic coverage targeted a balanced representation of markets to reflect variation in healthcare delivery and regulatory contexts. The study also acknowledges limitations, including the evolving nature of clinical evidence and potential variability in regional data availability, and recommends periodic updates and targeted primary studies for high-priority subtopics. Overall, the methodology emphasizes reproducibility, peer validation, and practical relevance for stakeholders involved in Graves disease care and commercial strategy.

A concise synthesis highlighting diagnostic and therapeutic progress alongside supply chain and policy challenges that require coordinated strategic action

This analysis underscores that Graves disease management is at an inflection point where diagnostic refinement, therapeutic innovation, and pragmatic operational planning converge to shape future standards of care. Improvements in serological assays and imaging techniques are enabling earlier, more accurate diagnosis, while evolving therapeutic options and care models offer the prospect of improved safety and patient-centered outcomes. However, these opportunities coexist with systemic challenges including supply chain vulnerabilities, tariff-related procurement complexities, and heterogeneous regional adoption patterns that require deliberate strategic responses.

In summary, stakeholders who align clinical development with real-world operational constraints, invest in resilient supply and distribution networks, and proactively engage payers and regulators will be best positioned to translate scientific advances into tangible patient benefits. Emphasizing integrated care pathways, evidence generation, and scalable delivery models will accelerate the adoption of innovations that improve quality of life for patients living with Graves disease while maintaining sustainable organizational performance.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Adoption of targeted biologic therapies aiming at B-cell modulation for refractory Graves disease management
  • 5.2. Integration of wearable thyroid function monitoring devices enabling real time TSH tracking and patient engagement
  • 5.3. Expansion of teleendocrinology platforms facilitating remote diagnosis and treatment adjustments for Graves disease patients
  • 5.4. Regulatory approval of novel small molecule TSH receptor antagonists expanding non invasive treatment options
  • 5.5. Growth in combination therapy protocols merging antithyroid drugs with immunomodulators to reduce relapse rates
  • 5.6. Emergence of patient centric digital health applications supporting symptom logging and medication adherence in Graves disease
  • 5.7. Clinical adoption of high intensity focused ultrasound as a non surgical alternative for Graves ophthalmopathy management

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Graves Disease Market, by Diagnosis

  • 8.1. Blood Tests
    • 8.1.1. Free T4 & T3 Levels
    • 8.1.2. Thyroid-stimulating Hormone (TSH) Levels
    • 8.1.3. TSH Receptor Antibodies (TSH-RAb)
  • 8.2. Imaging Tests
    • 8.2.1. Radioactive Iodine Uptake
    • 8.2.2. Thyroid Ultrasound
  • 8.3. Physical Examination

9. Graves Disease Market, by Treatment Type

  • 9.1. Antithyroid Medications
  • 9.2. Beta-Blockers
  • 9.3. Radioactive Iodine Therapy

10. Graves Disease Market, by Age Group

  • 10.1. Adult
  • 10.2. Elderly
  • 10.3. Pediatric

11. Graves Disease Market, by Route Of Administration

  • 11.1. Intravenous
  • 11.2. Oral

12. Graves Disease Market, by Distribution Channel

  • 12.1. Hospital Pharmacies
  • 12.2. Online Pharmacies
  • 12.3. Retail Pharmacies

13. Graves Disease Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Graves Disease Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Graves Disease Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Abbott Laboratories
    • 16.3.2. AdvanceCor GmbH
    • 16.3.3. Cadila Pharmaceuticals Limited
    • 16.3.4. CORONA Remedies Limited
    • 16.3.5. Daxia Healthcare Pvt Ltd.
    • 16.3.6. Eris Lifesciences Ltd
    • 16.3.7. F. Hoffmann-La Roche Ltd.
    • 16.3.8. Immunovant, Inc. by Roivant Sciences Ltd.
    • 16.3.9. LGM Pharma
    • 16.3.10. Macleods Pharmaceuticals Ltd.
    • 16.3.11. Merck KGaA
    • 16.3.12. Novartis AG
    • 16.3.13. Pfizer Inc.
    • 16.3.14. Salvavidas Pharmaceutical Pvt. Ltd.
    • 16.3.15. Siemens Healthineers AG
    • 16.3.16. Steris Healthcare Pvt Ltd
    • 16.3.17. Sun Pharmaceutical Industries Ltd
    • 16.3.18. Synmedic Laboratories by Dhanuka Laboratories Limited
    • 16.3.19. Teva Pharmaceutical Industries Ltd.
    • 16.3.20. Thermo Fisher Scientific Inc.
    • 16.3.21. Wellona Pharma

LIST OF FIGURES

  • FIGURE 1. GLOBAL GRAVES DISEASE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL GRAVES DISEASE MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL GRAVES DISEASE MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL GRAVES DISEASE MARKET SIZE, BY AGE GROUP, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL GRAVES DISEASE MARKET SIZE, BY AGE GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL GRAVES DISEASE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS GRAVES DISEASE MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA GRAVES DISEASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA GRAVES DISEASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA GRAVES DISEASE MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE GRAVES DISEASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST GRAVES DISEASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA GRAVES DISEASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC GRAVES DISEASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL GRAVES DISEASE MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN GRAVES DISEASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC GRAVES DISEASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION GRAVES DISEASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS GRAVES DISEASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 GRAVES DISEASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO GRAVES DISEASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL GRAVES DISEASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. GRAVES DISEASE MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. GRAVES DISEASE MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. GRAVES DISEASE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL GRAVES DISEASE MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL GRAVES DISEASE MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL GRAVES DISEASE MARKET SIZE, BY FREE T4 & T3 LEVELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL GRAVES DISEASE MARKET SIZE, BY FREE T4 & T3 LEVELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL GRAVES DISEASE MARKET SIZE, BY FREE T4 & T3 LEVELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL GRAVES DISEASE MARKET SIZE, BY FREE T4 & T3 LEVELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL GRAVES DISEASE MARKET SIZE, BY FREE T4 & T3 LEVELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL GRAVES DISEASE MARKET SIZE, BY FREE T4 & T3 LEVELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL GRAVES DISEASE MARKET SIZE, BY THYROID-STIMULATING HORMONE (TSH) LEVELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL GRAVES DISEASE MARKET SIZE, BY THYROID-STIMULATING HORMONE (TSH) LEVELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL GRAVES DISEASE MARKET SIZE, BY THYROID-STIMULATING HORMONE (TSH) LEVELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL GRAVES DISEASE MARKET SIZE, BY THYROID-STIMULATING HORMONE (TSH) LEVELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL GRAVES DISEASE MARKET SIZE, BY THYROID-STIMULATING HORMONE (TSH) LEVELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL GRAVES DISEASE MARKET SIZE, BY THYROID-STIMULATING HORMONE (TSH) LEVELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL GRAVES DISEASE MARKET SIZE, BY TSH RECEPTOR ANTIBODIES (TSH-RAB), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL GRAVES DISEASE MARKET SIZE, BY TSH RECEPTOR ANTIBODIES (TSH-RAB), BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL GRAVES DISEASE MARKET SIZE, BY TSH RECEPTOR ANTIBODIES (TSH-RAB), BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL GRAVES DISEASE MARKET SIZE, BY TSH RECEPTOR ANTIBODIES (TSH-RAB), BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL GRAVES DISEASE MARKET SIZE, BY TSH RECEPTOR ANTIBODIES (TSH-RAB), BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL GRAVES DISEASE MARKET SIZE, BY TSH RECEPTOR ANTIBODIES (TSH-RAB), BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL GRAVES DISEASE MARKET SIZE, BY RADIOACTIVE IODINE UPTAKE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL GRAVES DISEASE MARKET SIZE, BY RADIOACTIVE IODINE UPTAKE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL GRAVES DISEASE MARKET SIZE, BY RADIOACTIVE IODINE UPTAKE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL GRAVES DISEASE MARKET SIZE, BY RADIOACTIVE IODINE UPTAKE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL GRAVES DISEASE MARKET SIZE, BY RADIOACTIVE IODINE UPTAKE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL GRAVES DISEASE MARKET SIZE, BY RADIOACTIVE IODINE UPTAKE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL GRAVES DISEASE MARKET SIZE, BY THYROID ULTRASOUND, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL GRAVES DISEASE MARKET SIZE, BY THYROID ULTRASOUND, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL GRAVES DISEASE MARKET SIZE, BY THYROID ULTRASOUND, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL GRAVES DISEASE MARKET SIZE, BY THYROID ULTRASOUND, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL GRAVES DISEASE MARKET SIZE, BY THYROID ULTRASOUND, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL GRAVES DISEASE MARKET SIZE, BY THYROID ULTRASOUND, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL GRAVES DISEASE MARKET SIZE, BY PHYSICAL EXAMINATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL GRAVES DISEASE MARKET SIZE, BY PHYSICAL EXAMINATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL GRAVES DISEASE MARKET SIZE, BY PHYSICAL EXAMINATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL GRAVES DISEASE MARKET SIZE, BY PHYSICAL EXAMINATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL GRAVES DISEASE MARKET SIZE, BY PHYSICAL EXAMINATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL GRAVES DISEASE MARKET SIZE, BY PHYSICAL EXAMINATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL GRAVES DISEASE MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL GRAVES DISEASE MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL GRAVES DISEASE MARKET SIZE, BY ANTITHYROID MEDICATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL GRAVES DISEASE MARKET SIZE, BY ANTITHYROID MEDICATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL GRAVES DISEASE MARKET SIZE, BY ANTITHYROID MEDICATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL GRAVES DISEASE MARKET SIZE, BY ANTITHYROID MEDICATIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL GRAVES DISEASE MARKET SIZE, BY ANTITHYROID MEDICATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL GRAVES DISEASE MARKET SIZE, BY ANTITHYROID MEDICATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL GRAVES DISEASE MARKET SIZE, BY BETA-BLOCKERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL GRAVES DISEASE MARKET SIZE, BY RADIOACTIVE IODINE THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL GRAVES DISEASE MARKET SIZE, BY RADIOACTIVE IODINE THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL GRAVES DISEASE MARKET SIZE, BY RADIOACTIVE IODINE THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL GRAVES DISEASE MARKET SIZE, BY RADIOACTIVE IODINE THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL GRAVES DISEASE MARKET SIZE, BY RADIOACTIVE IODINE THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL GRAVES DISEASE MARKET SIZE, BY RADIOACTIVE IODINE THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL GRAVES DISEASE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL GRAVES DISEASE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL GRAVES DISEASE MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL GRAVES DISEASE MARKET SIZE, BY ADULT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL GRAVES DISEASE MARKET SIZE, BY ADULT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL GRAVES DISEASE MARKET SIZE, BY ADULT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL GRAVES DISEASE MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL GRAVES DISEASE MARKET SIZE, BY ADULT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL GRAVES DISEASE MARKET SIZE, BY ELDERLY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL GRAVES DISEASE MARKET SIZE, BY ELDERLY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL GRAVES DISEASE MARKET SIZE, BY ELDERLY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL GRAVES DISEASE MARKET SIZE, BY ELDERLY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL GRAVES DISEASE MARKET SIZE, BY ELDERLY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL GRAVES DISEASE MARKET SIZE, BY ELDERLY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL GRAVES DISEASE MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL GRAVES DISEASE MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL GRAVES DISEASE MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL GRAVES DISEASE MARKET SIZE, BY PEDIATRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL GRAVES DISEASE MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL GRAVES DISEASE MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL GRAVES DISEASE MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL GRAVES DISEASE MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL GRAVES DISEASE MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL GRAVES DISEASE MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL GRAVES DISEASE MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL GRAVES DISEASE MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL GRAVES DISEASE MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL GRAVES DISEASE MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL GRAVES DISEASE MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL GRAVES DISEASE MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL GRAVES DISEASE MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL GRAVES DISEASE MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL GRAVES DISEASE MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL GRAVES DISEASE MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL GRAVES DISEASE MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL GRAVES DISEASE MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL GRAVES DISEASE MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL GRAVES DISEASE MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL GRAVES DISEASE MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL GRAVES DISEASE MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL GRAVES DISEASE MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL GRAVES DISEASE MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL GRAVES DISEASE MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL GRAVES DISEASE MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL GRAVES DISEASE MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL GRAVES DISEASE MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL GRAVES DISEASE MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL GRAVES DISEASE MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL GRAVES DISEASE MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL GRAVES DISEASE MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL GRAVES DISEASE MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL GRAVES DISEASE MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. AMERICAS GRAVES DISEASE MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 136. AMERICAS GRAVES DISEASE MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 137. AMERICAS GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2024 (USD MILLION)
  • TABLE 138. AMERICAS GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2025-2032 (USD MILLION)
  • TABLE 139. AMERICAS GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2024 (USD MILLION)
  • TABLE 140. AMERICAS GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2025-2032 (USD MILLION)
  • TABLE 141. AMERICAS GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2024 (USD MILLION)
  • TABLE 142. AMERICAS GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2025-2032 (USD MILLION)
  • TABLE 143. AMERICAS GRAVES DISEASE MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 144. AMERICAS GRAVES DISEASE MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 145. AMERICAS GRAVES DISEASE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. AMERICAS GRAVES DISEASE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. AMERICAS GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 148. AMERICAS GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 149. AMERICAS GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 150. AMERICAS GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA GRAVES DISEASE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. NORTH AMERICA GRAVES DISEASE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2024 (USD MILLION)
  • TABLE 154. NORTH AMERICA GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2025-2032 (USD MILLION)
  • TABLE 155. NORTH AMERICA GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2024 (USD MILLION)
  • TABLE 156. NORTH AMERICA GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2025-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2024 (USD MILLION)
  • TABLE 158. NORTH AMERICA GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2025-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA GRAVES DISEASE MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 160. NORTH AMERICA GRAVES DISEASE MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 161. NORTH AMERICA GRAVES DISEASE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. NORTH AMERICA GRAVES DISEASE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 164. NORTH AMERICA GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 166. NORTH AMERICA GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA GRAVES DISEASE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. LATIN AMERICA GRAVES DISEASE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. LATIN AMERICA GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2024 (USD MILLION)
  • TABLE 170. LATIN AMERICA GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2025-2032 (USD MILLION)
  • TABLE 171. LATIN AMERICA GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2024 (USD MILLION)
  • TABLE 172. LATIN AMERICA GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2025-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2024 (USD MILLION)
  • TABLE 174. LATIN AMERICA GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2025-2032 (USD MILLION)
  • TABLE 175. LATIN AMERICA GRAVES DISEASE MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 176. LATIN AMERICA GRAVES DISEASE MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 177. LATIN AMERICA GRAVES DISEASE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. LATIN AMERICA GRAVES DISEASE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 180. LATIN AMERICA GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 181. LATIN AMERICA GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 182. LATIN AMERICA GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 183. EUROPE, MIDDLE EAST & AFRICA GRAVES DISEASE MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 184. EUROPE, MIDDLE EAST & AFRICA GRAVES DISEASE MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 185. EUROPE, MIDDLE EAST & AFRICA GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2024 (USD MILLION)
  • TABLE 186. EUROPE, MIDDLE EAST & AFRICA GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2025-2032 (USD MILLION)
  • TABLE 187. EUROPE, MIDDLE EAST & AFRICA GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2024 (USD MILLION)
  • TABLE 188. EUROPE, MIDDLE EAST & AFRICA GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2025-2032 (USD MILLION)
  • TABLE 189. EUROPE, MIDDLE EAST & AFRICA GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2024 (USD MILLION)
  • TABLE 190. EUROPE, MIDDLE EAST & AFRICA GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2025-2032 (USD MILLION)
  • TABLE 191. EUROPE, MIDDLE EAST & AFRICA GRAVES DISEASE MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 192. EUROPE, MIDDLE EAST & AFRICA GRAVES DISEASE MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 193. EUROPE, MIDDLE EAST & AFRICA GRAVES DISEASE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. EUROPE, MIDDLE EAST & AFRICA GRAVES DISEASE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. EUROPE, MIDDLE EAST & AFRICA GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 199. EUROPE GRAVES DISEASE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. EUROPE GRAVES DISEASE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. EUROPE GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2024 (USD MILLION)
  • TABLE 202. EUROPE GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2025-2032 (USD MILLION)
  • TABLE 203. EUROPE GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2024 (USD MILLION)
  • TABLE 204. EUROPE GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2025-2032 (USD MILLION)
  • TABLE 205. EUROPE GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2024 (USD MILLION)
  • TABLE 206. EUROPE GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2025-2032 (USD MILLION)
  • TABLE 207. EUROPE GRAVES DISEASE MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 208. EUROPE GRAVES DISEASE MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 209. EUROPE GRAVES DISEASE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 210. EUROPE GRAVES DISEASE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 211. EUROPE GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 212. EUROPE GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 213. EUROPE GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 214. EUROPE GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 215. MIDDLE EAST GRAVES DISEASE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. MIDDLE EAST GRAVES DISEASE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. MIDDLE EAST GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2024 (USD MILLION)
  • TABLE 218. MIDDLE EAST GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2025-2032 (USD MILLION)
  • TABLE 219. MIDDLE EAST GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2024 (USD MILLION)
  • TABLE 220. MIDDLE EAST GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2025-2032 (USD MILLION)
  • TABLE 221. MIDDLE EAST GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2024 (USD MILLION)
  • TABLE 222. MIDDLE EAST GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2025-2032 (USD MILLION)
  • TABLE 223. MIDDLE EAST GRAVES DISEASE MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 224. MIDDLE EAST GRAVES DISEASE MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 225. MIDDLE EAST GRAVES DISEASE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 226. MIDDLE EAST GRAVES DISEASE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 227. MIDDLE EAST GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 228. MIDDLE EAST GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 229. MIDDLE EAST GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 230. MIDDLE EAST GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 231. AFRICA GRAVES DISEASE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 232. AFRICA GRAVES DISEASE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 233. AFRICA GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2024 (USD MILLION)
  • TABLE 234. AFRICA GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2025-2032 (USD MILLION)
  • TABLE 235. AFRICA GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2024 (USD MILLION)
  • TABLE 236. AFRICA GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2025-2032 (USD MILLION)
  • TABLE 237. AFRICA GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2024 (USD MILLION)
  • TABLE 238. AFRICA GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2025-2032 (USD MILLION)
  • TABLE 239. AFRICA GRAVES DISEASE MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 240. AFRICA GRAVES DISEASE MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 241. AFRICA GRAVES DISEASE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 242. AFRICA GRAVES DISEASE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 243. AFRICA GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 244. AFRICA GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 245. AFRICA GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 246. AFRICA GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 247. ASIA-PACIFIC GRAVES DISEASE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 248. ASIA-PACIFIC GRAVES DISEASE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 249. ASIA-PACIFIC GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2024 (USD MILLION)
  • TABLE 250. ASIA-PACIFIC GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2025-2032 (USD MILLION)
  • TABLE 251. ASIA-PACIFIC GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2024 (USD MILLION)
  • TABLE 252. ASIA-PACIFIC GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2025-2032 (USD MILLION)
  • TABLE 253. ASIA-PACIFIC GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2024 (USD MILLION)
  • TABLE 254. ASIA-PACIFIC GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2025-2032 (USD MILLION)
  • TABLE 255. ASIA-PACIFIC GRAVES DISEASE MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 256. ASIA-PACIFIC GRAVES DISEASE MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 257. ASIA-PACIFIC GRAVES DISEASE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 258. ASIA-PACIFIC GRAVES DISEASE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 259. ASIA-PACIFIC GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 260. ASIA-PACIFIC GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 261. ASIA-PACIFIC GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 262. ASIA-PACIFIC GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL GRAVES DISEASE MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL GRAVES DISEASE MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 265. ASEAN GRAVES DISEASE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 266. ASEAN GRAVES DISEASE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 267. ASEAN GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2024 (USD MILLION)
  • TABLE 268. ASEAN GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2025-2032 (USD MILLION)
  • TABLE 269. ASEAN GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2024 (USD MILLION)
  • TABLE 270. ASEAN GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2025-2032 (USD MILLION)
  • TABLE 271. ASEAN GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2024 (USD MILLION)
  • TABLE 272. ASEAN GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2025-2032 (USD MILLION)
  • TABLE 273. ASEAN GRAVES DISEASE MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 274. ASEAN GRAVES DISEASE MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 275. ASEAN GRAVES DISEASE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 276. ASEAN GRAVES DISEASE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 277. ASEAN GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 278. ASEAN GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 279. ASEAN GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 280. ASEAN GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 281. GCC GRAVES DISEASE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 282. GCC GRAVES DISEASE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 283. GCC GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2024 (USD MILLION)
  • TABLE 284. GCC GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2025-2032 (USD MILLION)
  • TABLE 285. GCC GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2024 (USD MILLION)
  • TABLE 286. GCC GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2025-2032 (USD MILLION)
  • TABLE 287. GCC GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2024 (USD MILLION)
  • TABLE 288. GCC GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2025-2032 (USD MILLION)
  • TABLE 289. GCC GRAVES DISEASE MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 290. GCC GRAVES DISEASE MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 291. GCC GRAVES DISEASE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 292. GCC GRAVES DISEASE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 293. GCC GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 294. GCC GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 295. GCC GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 296. GCC GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 297. EUROPEAN UNION GRAVES DISEASE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 298. EUROPEAN UNION GRAVES DISEASE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 299. EUROPEAN UNION GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2024 (USD MILLION)
  • TABLE 300. EUROPEAN UNION GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2025-2032 (USD MILLION)
  • TABLE 301. EUROPEAN UNION GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2024 (USD MILLION)
  • TABLE 302. EUROPEAN UNION GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2025-2032 (USD MILLION)
  • TABLE 303. EUROPEAN UNION GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2024 (USD MILLION)
  • TABLE 304. EUROPEAN UNION GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2025-2032 (USD MILLION)
  • TABLE 305. EUROPEAN UNION GRAVES DISEASE MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 306. EUROPEAN UNION GRAVES DISEASE MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 307. EUROPEAN UNION GRAVES DISEASE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 308. EUROPEAN UNION GRAVES DISEASE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 309. EUROPEAN UNION GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 310. EUROPEAN UNION GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 311. EUROPEAN UNION GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 312. EUROPEAN UNION GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 313. BRICS GRAVES DISEASE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 314. BRICS GRAVES DISEASE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 315. BRICS GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2024 (USD MILLION)
  • TABLE 316. BRICS GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2025-2032 (USD MILLION)
  • TABLE 317. BRICS GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2024 (USD MILLION)
  • TABLE 318. BRICS GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2025-2032 (USD MILLION)
  • TABLE 319. BRICS GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2024 (USD MILLION)
  • TABLE 320. BRICS GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2025-2032 (USD MILLION)
  • TABLE 321. BRICS GRAVES DISEASE MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 322. BRICS GRAVES DISEASE MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 323. BRICS GRAVES DISEASE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 324. BRICS GRAVES DISEASE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 325. BRICS GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 326. BRICS GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 327. BRICS GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 328. BRICS GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 329. G7 GRAVES DISEASE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 330. G7 GRAVES DISEASE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 331. G7 GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2024 (USD MILLION)
  • TABLE 332. G7 GRAVES DISEASE MARKET SIZE, BY DIAGNOSIS, 2025-2032 (USD MILLION)
  • TABLE 333. G7 GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2018-2024 (USD MILLION)
  • TABLE 334. G7 GRAVES DISEASE MARKET SIZE, BY BLOOD TESTS, 2025-2032 (USD MILLION)
  • TABLE 335. G7 GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2018-2024 (USD MILLION)
  • TABLE 336. G7 GRAVES DISEASE MARKET SIZE, BY IMAGING TESTS, 2025-2032 (USD MILLION)
  • TABLE 337. G7 GRAVES DISEASE MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 338. G7 GRAVES DISEASE MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 339. G7 GRAVES DISEASE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 340. G7 GRAVES DISEASE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 341. G7 GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 342. G7 GRAVES DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 343. G7 GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 344. G7 GRAVES DISEASE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 345. NATO GRAVES DISEASE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 346. NATO GRAVES DISEASE MARKET SIZE, BY COUNTR